REFERENCES

1. Singal AK, Mathurin P. Diagnosis and treatment of alcohol-associated liver disease: a review. JAMA. 2021;326:165-76.

2. Singal AK, Arsalan A, Dunn W, et al. Alcohol-associated liver disease in the United States is associated with severe forms of disease among young, females and Hispanics. Aliment Pharmacol Ther. 2021;54:451-61.

3. Arab JP, Louvet A, Thiele M, Winder GS, Wong RJ, Singal AK. Alcohol-associated liver disease: managing the dual pathology of liver disease and of alcohol use disorder. Gastroenterology. 2025;168:231-44.e2.

4. Hasin DS, O’brien CP, Auriacombe M, et al. DSM-5 criteria for substance use disorders: recommendations and rationale. AJP. 2013;170:834-51.

5. Louvet A, Labreuche J, Artru F, et al. Main drivers of outcome differ between short term and long term in severe alcoholic hepatitis: a prospective study. Hepatology. 2017;66:1464-73.

6. Kodali S, Kaif M, Tariq R, Singal AK. Alcohol relapse after liver transplantation for alcoholic cirrhosis-impact on liver graft and patient survival: a meta-analysis. Alcohol Alcohol. 2018;53:166-72.

7. Rogal S, Youk A, Zhang H, et al. Impact of alcohol use disorder treatment on clinical outcomes among patients with cirrhosis. Hepatology. 2020;71:2080-92.

8. Vannier AGL, Shay JES, Fomin V, et al. Incidence and progression of alcohol-associated liver disease after medical therapy for alcohol use disorder. JAMA Netw Open. 2022;5:e2213014.

9. Hu H, Mitra R, Han Y, et al. Prevalence and treatment for alcohol use disorders based on kentucky medicaid 2012-2019 datasets. J Alcohol Drug Depend. 2022;10:1000366.

10. DiMartini AF, Leggio L, Singal AK. Barriers to the management of alcohol use disorder and alcohol-associated liver disease: strategies to implement integrated care models. Lancet Gastroenterol Hepatol. 2022;7:186-95.

11. Mellinger JL, Fernandez A, Shedden K, et al. Gender disparities in alcohol use disorder treatment among privately insured patients with alcohol-associated cirrhosis. Alcohol Clin Exp Res. 2019;43:334-41.

12. Keyes KM, Hatzenbuehler ML, McLaughlin KA, et al. Stigma and treatment for alcohol disorders in the United States. Am J Epidemiol. 2010;172:1364-72.

13. Singal AK, Leggio L, DiMartini A. Alcohol use disorder in alcohol-associated liver disease: two sides of the same coin. Liver Transpl. 2024;30:200-12.

14. Lennon-Dearing R, Florence J, Garrett L, Click IA, Abercrombie S. A rural community-based interdisciplinary curriculum: a social work perspective. Soc Work Health Care. 2008;47:93-107.

15. Wong RJ, Singal AK. Trends in liver disease etiology among adults awaiting liver transplantation in the United States, 2014-2019. JAMA Netw Open. 2020;3:e1920294.

16. Axley PD, Richardson CT, Singal AK. Epidemiology of alcohol consumption and societal burden of alcoholism and alcoholic liver disease. Clin Liver Dis. 2019;23:39-50.

17. Fuster D, Samet JH. Alcohol use in patients with chronic liver disease. N Engl J Med. 2018;379:1251-61.

18. Singal AK, Arora S, Wong RJ, et al. Increasing burden of acute-on-chronic liver failure among alcohol-associated liver disease in the young population in the United States. Am J Gastroenterol. 2020;115:88-95.

19. Jurewicz I. Mental health in young adults and adolescents - supporting general physicians to provide holistic care. Clin Med. 2015;15:151-4.

20. Tarantino G, Cataldi M, Citro V. Could alcohol abuse and dependence on junk foods inducing obesity and/or illicit drug use represent danger to liver in young people with altered psychological/relational spheres or emotional problems? Int J Mol Sci. 2022;23:10406.

21. Shoreibah M, Raff E, Bloomer J, et al. Alcoholic liver disease presents at advanced stage and progresses faster compared to non-alcoholic fatty liver diseas. Ann Hepatol. 2016;15:183-9.

22. Saraireh H, Redman J, Abdelfattah T, et al. Training of hepatology providers improves the screening and resultant interventions for alcohol use disorder. Liver Int. 2020;40:2090-4.

23. Wong RJ, Yang Z, Cheung R, et al. Impact of longitudinal alcohol use patterns on long-term risk of cirrhosis among US veterans with steatotic liver disease. Gastroenterology. 2024;166:1156-65.e4.

24. Im GY, Mellinger JL, Winters A, et al. Provider attitudes and practices for alcohol screening, treatment, and education in patients with liver disease: a survey from the american association for the study of liver diseases alcohol-associated liver disease special interest group. Clin Gastroenterol Hepatol. 2021;19:2407-16.e8.

25. Kaner EF, Dickinson HO, Beyer F, et al. The effectiveness of brief alcohol interventions in primary care settings: a systematic review. Drug Alcohol Rev. 2009;28:301-23.

26. Moyer VA; Preventive Services Task Force. Screening and behavioral counseling interventions in primary care to reduce alcohol misuse: U.S. preventive services task force recommendation statement. Ann Intern Med. 2013;159:210-8.

27. Kranzler HR, Soyka M. Diagnosis and pharmacotherapy of alcohol use disorder: a review. JAMA. 2018;320:815-24.

28. Louvet A, Labreuche J, Moreno C, et al; QuickTrans trial study group. Early liver transplantation for severe alcohol-related hepatitis not responding to medical treatment: a prospective controlled study. Lancet Gastroenterol Hepatol. 2022;7:416-25.

29. Sobell LC, Sobell MB. Timeline follow-back. In: Litten RZ, Allen JP, Editors. Measuring alcohol consumption. Totowa, NJ: Humana Press; 1992.

30. Kulkarni AV, Singal AK. Screening for alcohol use disorder and monitoring for alcohol use in the liver clinic. Clin Liver Dis. 2023;22:219-24.

31. Evidence-based practices in writing. Available from: https://www.silvereye.com.au/documents/sample_pages/prod9580.pdf. [Last accessed on 19 Mar 2025].

32. McHugh RK, Hearon BA, Otto MW. Cognitive behavioral therapy for substance use disorders. Psychiatr Clin North Am. 2010;33:511-25.

33. Morey LC. Patient placement criteria: linking typologies to managed care. Alcohol Health Res World. 1996;20:36-44.

34. Chuang E, Wells R, Alexander JA, Friedmann PD, Lee IH. Factors associated with use of ASAM criteria and service provision in a national sample of outpatient substance abuse treatment units. J Addict Med. 2009;3:139-50.

35. Ayyala D, Bottyan T, Tien C, et al. Naltrexone for alcohol use disorder: hepatic safety in patients with and without liver disease. Hepatol Commun. 2022;6:3433-42.

36. Caputo F, Domenicali M, Bernardi M. Diagnosis and treatment of alcohol use disorder in patients with end-stage alcoholic liver disease. Hepatology. 2019;70:410-7.

37. Burnette EM, Nieto SJ, Grodin EN, et al. Novel agents for the pharmacological treatment of alcohol use disorder. Drugs. 2022;82:251-74.

38. Leggio L, Lee MR. Treatment of alcohol use disorder in patients with alcoholic liver disease. Am J Med. 2017;130:124-34.

39. Addolorato G, Leggio L, Ferrulli A, et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet. 2007;370:1915-22.

40. Grant BF, Goldstein RB, Saha TD, et al. Epidemiology of DSM-5 alcohol use disorder: results from the national epidemiologic survey on alcohol and related conditions III. JAMA Psychiatry. 2015;72:757-66.

41. Stinson FS, Grant BF, Dawson DA, Ruan WJ, Huang B, Saha T. Comorbidity between DSM-IV alcohol and specific drug use disorders in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Drug Alcohol Depend. 2005;80:105-16.

42. Singal AK, DiMartini A, Leggio L, Arab JP, Kuo YF, Shah VH. Identifying alcohol use disorder in patients with cirrhosis reduces 30-days readmission rate. Alcohol Alcohol. 2022;57:576-80.

43. Elfeki MA, Abdallah MA, Leggio L, Singal AK. Simultaneous management of alcohol use disorder and liver disease: a systematic review and meta-analysis. J Addict Med. 2023;17:e119-28.

44. Mellinger JL, Scott Winder G, DeJonckheere M, et al. Misconceptions, preferences and barriers to alcohol use disorder treatment in alcohol-related cirrhosis. J Subst Abuse Treat. 2018;91:20-7.

45. Rabiee A, Mahmud N, Falker C, Garcia-Tsao G, Taddei T, Kaplan DE. Medications for alcohol use disorder improve survival in patients with hazardous drinking and alcohol-associated cirrhosis. Hepatol Commun. 2023;7:e0093.

46. Gratacós-Ginès J, Bruguera P, Pérez-Guasch M, et al. Medications for alcohol use disorder promote abstinence in alcohol-associated cirrhosis: results from a systematic review and meta-analysis. Hepatology. 2024;79:368-79.

47. Lucey MR, Singal AK. Integrated treatment of alcohol use disorder in patients with alcohol-associated liver disease: an evolving story. Hepatology. 2020;71:1891-3.

48. Szerman N, Torrens M, Maldonado R, et al; World Association on Dual Disorders (WADD). Addictive and other mental disorders: a call for a standardized definition of dual disorders. Transl Psychiatry. 2022;12:446.

49. DeMartini KS, Schilsky ML, Palmer A, et al. Text messaging to reduce alcohol relapse in prelisting liver transplant candidates: a pilot feasibility study. Alcohol Clin Exp Res. 2018;42:761-9.

50. Addolorato G, Mirijello A, Leggio L, et al; Gemelli OLT Group. Liver transplantation in alcoholic patients: impact of an alcohol addiction unit within a liver transplant center. Alcohol Clin Exp Res. 2013;37:1601-8.

51. Carrique L, Quance J, Tan A, et al. Results of early transplantation for alcohol-related cirrhosis: integrated addiction treatment with low rate of relapse. Gastroenterology. 2021;161:1896-06.e2.

52. Daniel J, Dumortier J, Del Bello A, et al. Integrating an addiction team into the management of patients transplanted for alcohol-associated liver disease reduces the risk of severe relapse. JHEP Rep. 2023;5:100832.

53. Avanceña ALV, Miller N, Uttal SE, Hutton DW, Mellinger JL. Cost-effectiveness of alcohol use treatments in patients with alcohol-related cirrhosis. J Hepatol. 2021;74:1286-94.

54. Lucey MR, Im GY, Mellinger JL, Szabo G, Crabb DW. Introducing the 2019 American association for the study of liver diseases guidance on alcohol-associated liver disease. Liver Transpl. 2020;26:14-6.

55. Singal AK, Bataller R, Ahn J, Kamath PS, Shah VH. ACG clinical guideline: alcoholic liver disease. Am J Gastroenterol. 2018;113:175-94.

56. Jophlin LL, Singal AK, Bataller R, et al. ACG clinical guideline: alcohol-associated liver disease. Am J Gastroenterol. 2024;119:30-54.

57. Association for the Study of the Liver. EASL clinical practice guidelines: management of alcohol-related liver disease. J Hepatol. 2018;69:154-81.

58. Russ KB, Chen NW, Kamath PS, Shah VH, Kuo YF, Singal AK. Alcohol use after liver transplantation is independent of liver disease etiology. Alcohol Alcohol. 2016;51:698-701.

59. Moreno C, Mueller S, Szabo G. Non-invasive diagnosis and biomarkers in alcohol-related liver disease. J Hepatol. 2019;70:273-83.

60. Hazelden Betty Ford Graduate School. What is an addiction counselor? Available from: https://www.hazeldenbettyford.org/graduate-school-addiction-studies/what-are-addiction-counselors. [Last accessed on 19 Mar 2025].

61. Papadimitriou G. The “Biopsychosocial Model”: 40 years of application in psychiatry. Psychiatriki. 2017;28:107-10.

62. Saxe Zerden L, Lombardi BM, Jones A. Social workers in integrated health care: improving care throughout the life course. Soc Work Health Care. 2019;58:142-9.

63. Dixie B. The impact of the biosound therapy system on post-acute withdrawal syndrome. Ph.D. Dissertation, the Faculty of Saybrook University, California, CA, 2018. Available from https://www.proquest.com/openview/b8441041beb904fef2e6bbfc7e024a58/1?pq-origsite=gscholar&cbl=18750&diss=y. [Last accessed on 17 Mar 2025].